TOP TIERMARKET NEWSWIRE
News & sentiment

IMMIX BIOPHARMA INC (IMMX) — News & AI sentiment

IMMIX BIOPHARMA INC (IMMX) news roundup. 7 stories aggregated over the last 30 days. Average 30-day sentiment is 49.1/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
0
30d stories
7
avg sentiment 49.1/100
Insider net (90d)
$0
0 buys · 0 sells
Congress (90d)
0
0 buys · 0 sells

IMMX news in the last 24 hours, 7 days, 30 days and 90 days

How much IMMX coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowIMMX storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days0—no coverage
Last 30 days749.1/100IMMX headlines →
Last 90 days2749.4/100IMMX headlines →

Latest stories on IMMX

Oct 20
Morgan Stanley initiates Immix Biopharma stock with overweight rating
Investing.com Analyst Ratings63 · neutralanalyst
Oct 20
Oct 5
Oct 5
Sep 30
Sep 30
Immix Biopharma, Inc. (IMMX) files 8-K
SEC 8-K50 · neutralgeneral
Sep 30
Citizens reiterates Immix Biopharma stock rating on trial data
Investing.com Analyst Ratings55 · neutralanalyst
Sep 30
Sep 29
Sep 29
Sep 29
Sep 29
Immix Biopharma prices $125M stock offering
Seeking Alpha24 · bearishgeneral
Sep 29
Sep 29
Sep 29
Sep 29
Sep 29
Immix Biopharma, Inc. (IMMX) files 8-K
SEC 8-K50 · neutralgeneral
Sep 29
Top BioTech SMidcap Stock: Mizuho Analyst Highlights IMMX
Investing.com Markets63 · neutralanalyst
Sep 16
Mizuho raises Immix Biopharma stock price target to $26 on expansion
Investing.com Analyst Ratings61 · neutralanalyst
Sep 15
Sep 15
Citizens reiterates Immix Biopharma stock rating on pipeline progress
Investing.com Analyst Ratings56 · neutralanalyst
Aug 14
Aug 11
H.C. Wainwright raises Immix Biopharma price target to $25
Investing.com Analyst Ratings61 · neutralanalyst
Aug 10
Aug 10
Open IMMX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →